CST1, DCC1, IFITM1 or MELK as markers for diagnosing stomach cancer

摘要

The present invention relates to a biomarker for gastric cancer, CST1 (cysteine proteinase inhibitor, type 2 family), DCC1 (Defective in sister chromatid cohesion homolog 1), IFITM1 (interferon induced transmembrane protein 1) or MELK (maternal embryonic leucine zipper kinase). More particularly, the present invention relates to a diagnostic composition for gastric cancer comprising an agent measuring the expression level of CST1, DCC1, IFITM1 or MELK, a kit comprising the composition, a method for detecting the marker, and a method for screening a therapeutic agent for gastric cancer using the marker.

主权项

1. A method for diagnosing a gastric cancer in a subject, comprising the steps of measuring an expression level of a DCC1 gene in a biological sample from a patient with suspected gastric cancer by contacting the sample with primers having the nucleotide sequences set forth in SEQ ID NO:3 and SEQ ID NO:4; comparing the expression level of the DCC1 gene with a normal control sample expression level of the DCC1 gene; and
diagnosing the patient with suspected gastric cancer as having gastric cancer when the expression level of the DCC1 gene in the biological sample from said patient is increased compared to the expression level of the DCC1 gene in the normal control sample.